Autoimmune chronic active hepatitis and primary biliary cirrhosis

Area of Science:

• Hepatology
• Autoimmune diseases
• Gastroenterology

Background:

• Autoimmune chronic active hepatitis (CAH) is a serious condition requiring effective management.
• Primary biliary cirrhosis (PBC) shares features with autoimmune CAH but has limited treatment options for the underlying disease.

Purpose of the Study:

• To outline treatment strategies for autoimmune CAH, focusing on remission induction and maintenance.
• To discuss management approaches for PBC, emphasizing complication control and supportive care.

Main Methods:

• Review of established and anecdotal treatments for autoimmune CAH and PBC.
• Focus on drug choices like prednisolone and azathioprine for autoimmune CAH.
• Exploration of therapies for PBC complications such as pruritus and osteoporosis.

Main Results:

• Autoimmune CAH shows high responsiveness to prednisolone and azathioprine, prolonging life but rarely curing the disease.
• Complete withdrawal of treatment for autoimmune CAH leads to relapse in over 80% of patients.
• PBC treatment is largely unsuccessful for the underlying disease; management focuses on symptomatic relief and preventing complications like bone demineralization.

Conclusions:

• Effective treatment of autoimmune CAH involves inducing and maintaining remission with minimal side effects.
• PBC management should prioritize addressing complications, with liver transplantation offering a curative option.
• Calcium and vitamin D supplementation are recommended for PBC patients to prevent bone demineralization and osteomalacia.